Agree with Snobbish.
Given the poor track record on delivery, the latest update needs to be viewed with (learned) scepticism.
With the accounts not getting an audit sign-off for YEARS now, shareholders need a very clear and detailed explanation.
Has anyone understood the ~$800k spent on due diligence? A friend at PWC said that was an extraordinary amount of money.
I would also like an explanation as to why the current share price valuation is only 40c. The statement from Karam at the last AGM, while justifying the 20c issue to the cornerstone shareholder, was that ANY future issuance would be at >90c. The 40c valuation is based on yet another capital raise with again no transparency and offer to existing stakeholders. The NEW formula for 40c a share needs to be evidenced.
An independent director (Pusey represents the cornerstone investor) is desperately needed to guide the current directors in preparation for the promised listing.
- Forums
- IPOs
- E3Sixty Limited Pre-IPO Offer - Precious Metals Extraction from E-waste
E3Sixty Limited Pre-IPO Offer - Precious Metals Extraction from E-waste, page-163
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online